GSK strikes deal with Genmab

11.07.10 London/Copenhagen – British drugmaker GlaxoSmithKline has changed the conditions of its EUR1.2bn licensing agreement with Danish antibody specialist Genmab. GSK announced it will take over responsibility for developing Genmab’s... more

Report lauds biofuel potential

10.07.10 Copenhagen/Washington – Citing the report “The Future of Industrial Biorefineries” during a keynote address at the BIO World Congress conference in Washington at the end of June, the CEO of Danish biotech Novozymes, Steen... more

Genmab lays off CEO

10.07.10 A week before the UK’s National Institute for Clinical Excellence (NICE) refused reimbursing for GlaxoSmithKline’s leukemia drug Azerra (ofatumumab), Danish licenser Genmab A/S announced the resignation of CEO Lisa Drakeman.... more

GlaxoSmithKline and Genmab change conditions of Ofatumumab deal

05.07.10 London/Copenhagen – British drugmaker GlaxoSmithKline has changed the conditions of its EUR1.2bn licensing agreement with Danish antibody specialist Genmab. GSK announced it will take over responsibility for developing Genmab’s... more

Novozymes to produce cellulosic biofuel in China

28.05.10 Baegsvard – Danish enzyme specialist Novozyme has signed an agreement with the world’s third-largest oil refinery firm Sinopec, to provide enzymes for a cellulosic ethanol demonstration plant in China. The new plant, which will... more